Gilead to acquire cell therapy manufacturer for $7.8B

Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…

AI Summary: Gilead Sciences agreed to acquire Arcellx for $7.8 billion to secure manufacturing and commercialization of a leading multiple myeloma CAR‑T candidate. The deal folds Arcellx’s anito‑cel program into Gilead’s oncology portfolio, accelerating regulatory filings and scale‑up plans — because buying your way into cutting‑edge cell therapy apparently never goes out of style.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Gilead acquires Tubulis in multibillion-dollar push beyond HIV / 7 wks

Biogen announces $5.6B acquisition of Apellis Pharma / 1 month

Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 2 months

Servier to acquire Day One Biopharma for $2.5B / 2 months

Novartis closes Avidity deal; Atrium Therapeutics spinout launches / 2 months

FDA partially halts cancer trial following patient death and safety events / 3 months

Eli Lilly buys Orna to sprint into in‑vivo CAR‑T therapeutics / 3 months